Advancing Drug Development for the Prevention of Spontaneous Preterm Birth

Event

FDA Convening

Advancing Drug Development for the Prevention of Spontaneous Preterm Birth

Register
January 23, 2024 1:00PM - January 24, 2024 4:30PM

Virtual Public Meeting

Event Graphics Including Name Time and Date of Event

 

Advancing Drug Development for the

Prevention of Spontaneous Preterm Birth

 

January 23, 2024

1:00 - 4:30 PM ET

January 24, 2024

1:00 - 4:30 PM ET

 

In the United States, spontaneous preterm birth (sPTB) is the leading cause of infant mortality, with 1 in 10 babies being born preterm. Despite the significant impact and medical need, there are currently no US Food and Drug Administration (FDA) approved treatments for the prevention of sPTB. Duke-Margolis, under a cooperative agreement with the FDA, is a hosting a public virtual workshop on Advancing Drug Development for the Prevention of Spontaneous Preterm Birth. The workshop will bring together a multidisciplinary group of experts and individuals with lived experience to generate ideas and discussion around the challenges in developing and studying products to prevent preterm birth. Within the workshop speakers will cover the current landscape, challenges, and perspectives on preterm birth and expert panels will discuss the ethical, regulatory, and efficacy measurement considerations for clinical development programs for products intended to prevent preterm birth.

Workshop Recordings

 

Day 1

 

Day 2

Duke-Margolis Planning Team

Beth Boyer headshot

Beth Boyer, MPH

Policy Research Associate

Cameron Joyce Headshot

Cameron Joyce, MPA

Senior Policy Analyst

Dure Kim Headshot

Dure Kim, PharmD

Assistant Research Director

Mia Williams Headshot

Mia Williams, MPH

Policy Analyst